Cytosorbents (CTSO) PT Set at $15.00 by HC Wainwright

Cytosorbents (NASDAQ:CTSO) received a $15.00 price target from HC Wainwright in a research report issued to clients and investors on Wednesday. The firm presently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price objective indicates a potential upside of 45.49% from the company’s previous close.

Several other equities analysts also recently weighed in on CTSO. BidaskClub downgraded shares of Cytosorbents from a “buy” rating to a “hold” rating in a report on Friday, August 10th. Cowen reaffirmed a “buy” rating and set a $15.00 price target on shares of Cytosorbents in a report on Friday, August 3rd. Finally, Maxim Group reaffirmed a “buy” rating and set a $18.00 price target on shares of Cytosorbents in a report on Tuesday, September 4th. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $14.81.

Shares of CTSO traded down $0.40 on Wednesday, reaching $10.31. The company’s stock had a trading volume of 2,940 shares, compared to its average volume of 215,064. The company has a current ratio of 8.82, a quick ratio of 8.60 and a debt-to-equity ratio of 0.46. The company has a market cap of $303.58 million, a price-to-earnings ratio of -32.69 and a beta of 0.62. Cytosorbents has a 12-month low of $5.80 and a 12-month high of $14.95.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Wednesday, November 7th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. The company had revenue of $5.74 million for the quarter, compared to the consensus estimate of $5.79 million. Cytosorbents had a negative net margin of 70.97% and a negative return on equity of 96.98%. As a group, analysts predict that Cytosorbents will post -0.56 EPS for the current fiscal year.

In other news, COO Vincent Capponi sold 9,565 shares of Cytosorbents stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $13.00, for a total transaction of $124,345.00. Following the sale, the chief operating officer now owns 342,333 shares in the company, valued at $4,450,329. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Phillip P. Chan sold 5,787 shares of Cytosorbents stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $14.85, for a total transaction of $85,936.95. The disclosure for this sale can be found here. Insiders have sold 65,501 shares of company stock worth $927,310 in the last ninety days. Insiders own 6.90% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in CTSO. Pegasus Partners Ltd. bought a new stake in shares of Cytosorbents during the second quarter valued at approximately $114,000. Metropolitan Life Insurance Co. NY bought a new stake in shares of Cytosorbents during the second quarter valued at approximately $119,000. P.A.W. Capital Corp bought a new stake in shares of Cytosorbents during the third quarter valued at approximately $129,000. Pitcairn Co. bought a new stake in shares of Cytosorbents during the third quarter valued at approximately $147,000. Finally, Mycio Wealth Partners LLC bought a new stake in shares of Cytosorbents during the third quarter valued at approximately $166,000. Hedge funds and other institutional investors own 24.79% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Further Reading: Earnings Per Share

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply